Volition Issues Business Review 2024

Core Insights - VolitionRx Limited is positioned to revolutionize the diagnosis and monitoring of life-altering diseases for both animals and humans as it enters 2025 [1] Achievements in 2024 - Expanded access to the Nu.Q® Vet Cancer Test, now available in 20 countries, with over 110,000 tests sold in the first three quarters of 2024 [7] - Hosted a Satellite Symposium at the European Society of Intensive Care Medicine 2024, showcasing the clinical utility of Nu.Q® NETs in over 3,000 intensive care sepsis patients [7] - Strengthened the strategic patent portfolio and made significant progress in clinical and research programs within the cancer pillar [7] - Initiated commercial discussions for out-licensing opportunities in large markets such as sepsis and oncology liquid biopsy [7] - Appointed Timothy Still as Chair and Dr. Ethel Rubin as Independent Director to enhance the Board of Directors with significant commercial and financing experience in the diagnostic sector [7] Research and Development Focus - Volition is dedicated to developing cost-effective blood tests for diagnosing and monitoring diseases, including cancers and conditions associated with NETosis, such as sepsis [4] - The company's research and development activities are primarily based in Belgium, with additional offices in the U.S., London, and Singapore [5]